NOVELCARE
As powerful as cortisone - without its risks.
Why We Exist
-
is the foundation of a good life. Modern medicine, however, often relies on synthetic drugs that come with risks and side effects.
-
holds the key. The most powerful medicines in history - penicillin, morphine, aspirin, insulin - all originate from nature, not from laboratories.
-
We carry on this tradition. Our ingredient NPE® is a next-generation plant-based therapeutic - designed to heal without side effects.
Pain Point
Worldwide, over 204 million people suffer from eczema (atopic dermatitis).¹
The standard therapy is cortisone — effective, but with sometimes severe side effects and decreasing efficacy over long-term use.
Market Gap:
There is no compelling, safe alternative on the market.
The solution is our USP
NPE®
NPE® is a unique, highly effective, and natural plant extract with the anti-inflammatory power of cortisone — yet without its side effects.
Its effectiveness remains consistent even with repeated use — without resistance or skin damage.
Results after 2 days NPE® Lotion
The Product
Novelcare Lotion
Topical cream with NPE®.
Ready-to-use Product.
No resistance development.
No known side effects.
The true cortisone alternative for skin inflammations.
Spectacular Results
Successful Pilot Study
Published study on anti-inflammatory effects during cancer radiotherapy presented by Assoc. Prof. Dr. Zwahlen, President of the Swiss Society of Radiation Oncology (SRO)
Risk reduction of inflammatory skin reactions in radiotherapy patients by
50%
100% protection against grade 3 radiation dermatitis in the NPE group.
*Int J Breast Cancer. 2018 Jul 2;2018:2479274. doi: 10.1155/2018/2479274
Why we win!
-
No other full-spectrum extract meets our standards in purity, stability, solubility, bioavailability, and therapeutic efficacy.
-
The unique extraction process was developed and optimized by Dr. Holzgang over more than 20 years.
-
The production process is protected know-how and safeguarded against replication.
Market Potential
Atopic dermatitis is one of the most common skin diseases worldwide—affecting up to 20% of children and 10% of adults.
The global market for dermatological products is growing rapidly: from $20 billion (2020) to over $59 billion by 2030 (CAGR 11.5%).
Positioning:
Despite this growth, a safe and effective alternative to cortisone is missing. Novelcare fills this gap.
Investment Case
Phase 1 fully funded ✅
-
3.5 million CHF to fund the Phase II study (proof of concept)
-
After completing Phase 2 in 2028, through sale to big pharma.
-
J&J paid 1.25 billion CHF (2024) for a Zurich-based neurodermatitis startup.
Pfizer acquired Anacor (2016) for 5.2 billion USD—eczema gel after Phase II.
“Tomorrow’s medicine starts with what nature already knows.”
— Dr. Hans E. Holzgang, Founder Novelcare
